Psyence End Period Cash Flow from 2010 to 2024

PBMWW Stock   0.01  0.0005  6.76%   
Psyence Biomedical End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, Psyence Biomedical End Period Cash Flow regression line of quarterly data had mean square error of 62 B and geometric mean of  1,568,006. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
733.2 K
Current Value
M
Quarterly Volatility
321.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Psyence Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Psyence Biomedical's main balance sheet or income statement drivers, such as Interest Income of 1.4 K, Selling General Administrative of 1.8 M or Selling And Marketing Expenses of 84.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 0.0 or Days Sales Outstanding of 0.0. Psyence financial statements analysis is a perfect complement when working with Psyence Biomedical Valuation or Volatility modules.
  
Check out the analysis of Psyence Biomedical Correlation against competitors.

Latest Psyence Biomedical's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Psyence Biomedical Ltd over the last few years. It is Psyence Biomedical's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Psyence Biomedical's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Psyence End Period Cash Flow Regression Statistics

Arithmetic Mean1,609,817
Geometric Mean1,568,006
Coefficient Of Variation19.96
Mean Deviation232,353
Median1,755,038
Standard Deviation321,396
Sample Variance103.3B
Range1M
R-Value(0.67)
Mean Square Error62B
R-Squared0.44
Significance0.01
Slope(47,803)
Total Sum of Squares1.4T

Psyence End Period Cash Flow History

2024M
2023733.2 K
20221.3 M

About Psyence Biomedical Financial Statements

Psyence Biomedical investors use historical fundamental indicators, such as Psyence Biomedical's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Psyence Biomedical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow733.2 KM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Psyence Stock Analysis

When running Psyence Biomedical's price analysis, check to measure Psyence Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Psyence Biomedical is operating at the current time. Most of Psyence Biomedical's value examination focuses on studying past and present price action to predict the probability of Psyence Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Psyence Biomedical's price. Additionally, you may evaluate how the addition of Psyence Biomedical to your portfolios can decrease your overall portfolio volatility.